7th Annual Neuroscience Innovation Forum

Actinogen is a late Phase 2 clinical-stage biopharmaceutical company developing a once-a-day oral small molecule to treat Alzheimer's Disease and Major Depressive Disorder. Its lead molecule Xanamem works by controlling levels of the "stress hormone" cortisol in the brain without altering plasma cortisol. Cortisol levels have long been associated with both AD and MDD and in a recent Phase 2a clinically and statistically signficant improvements were seen in depressive symptoms. A phase 2b/3 is on-going in AD in Australia and the US.

AlgoTx develops innovative solutions for complex pain. The ongoing Phase 2 ACT trial (US EU) assesses the efficacy of ATX01 in Chemotherapy-Induced Peripheral Neuropathy (FDA Fast-Track), whilst the Phase 2 EASE trial (US EU) focuses on the orphan disease Erythromelalgia (US & EU ODD, FDA Fast-Track.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We recently completed Phase 2 studies of our lead candidate, zervimesine (CT1812) in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease, and geographic atrophy secondary to dry AMD. The Phase 2 START Study (NCT05531656) in early Alzheimer’s disease is ongoing. We believe zervimesine can regulate pathways that are impaired in these diseases through its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases.

CuraSen was established Oct 2018 with the goal of revitalizing lost adrenergic stimuli to the brains of patients with AD, PD and many other neurodegenerative diseases, whose cognitive capacities and daily activities continue to deteriorate without restorative, life-improving therapeutic options. This sadly remains evident in most patients with neurodegenerative disease despite recent approval milestones in AD. CuraSen’s candidates rapidly improve cognition, memory, attentiveness and emotional strength, all via action on a clinically proven medicinal pathway. Our unique combination drug approach allows safe, well-tolerated and brain-selective activation of adrenoceptors - normally essential for maintenance of cognition and mood - whose stimulation diminishes in the earliest prodromal periods of degeneration due to decline in integrity of the pontine locus coeruleus, source of the limbic and cortical norepinephrine (noradrenaline). CuraSen has recently achieved clinical proof of concept for two combinations therapeutic, CuraCN & CuraXN, in AD and PD patient studies, within a treatment period as short as 2-weeks. Longer term durability and dose ranging studies are planned, which will enable fuller elaboration of the breadth and magnitude of clinical improvement, as well as impact un underlying pathological hallmarks.

Founded in 1973, HanAll Biopharma has been at the forefront of scientific innovation, consistently striving to evolve and adapt for the benefit of patients. Our company has actively engaged in collaborations with diverse multinational companies, working together to provide patients with high-value medicines. In 2007, HanAll embarked on a new venture into the field of biopharmaceuticals. By establishing research and development centers in the United States, we successfully positioned ourselves to enter the global market. This strategic move underscored our commitment to expanding our reach and contributing to the global healthcare landscape. Subsequently, Hanall extended our presence to include Japan and Indonesia. HanAll's unwavering dedication to improving patient outcomes remains steadfast. We relentlessly explore uncharted territories in the pursuit of treatment options for individuals afflicted by rare and intractable diseases. Hanall is at the forefront of revolutionizing lives through an exceptional range of pharmaceutical products. Our extensive expertise encompasses various fields such as endocrine, circulatory, and urologic diseases. By demonstrating a profound understanding of immunology, we have propelled ourselves into new territories, broadening our focus to include immunology, oncology, neurology and ophthalmology. We strive to deliver first-in-class and best-in-class therapeutics to meet the unmet medical needs of patients through the advancement of science. We pursue innovation through strong ethical considerations and a performance, collaborative-oriented culture. Our successful development of multiple therapeutics from discovery through submission is driven by investing in strong protein development resources. In accordance with our vision, we have committed to our innovation, successful partnerships, and investments in the artificial intelligence (AI) space.

IAMA Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative treatments for central nervous system disorders. The company’s lead compound, IAMA-6, is a selective NKCC1 inhibitor designed to restore chloride homeostasis and rebalance GABAergic signaling in conditions such as autism, epilepsy, and other neurodevelopmental disorders. With a successfully completed phase 1 study, IAMA-6 is progressing to Phase 2 proof of concept studies.

Minoryx is a privately held late-stage single asset company located in Barcelona (Spain) that is developing leriglitazone, an oral small molecule, for rare CNS disorders. For its lead indication (cerebral Adrenoleukodystrophy, cALD), a marketing authorization application has been filed in EU in July 2025, while in the US the company is conducting a phase 3. Additionally, the company is conducting a phase 2a study in Rett Syndrome.

A public clinical-stage biopharma company developing epigenetics for CNS disorders and oncology/hematology. c.50 highly-qualified professionals located in Barcelona, Boston and San Diego. Listed in Spain, aiming at NASDAQ-listing. Two uncorrelated clinical-stage compounds: vafidemstat (Phase III-ready, CNS) and iadademstat (Phase II, oncology/hematology). Pioneering development of epigenetic drugs in CNS with vafidemstat, a safe LSD1 inhibitor, administered to + 425 subjects. The drug has shown promising results in reducing agitation/aggression in psychiatric patients in a Phase IIa basket trial, and in a global randomized, double blind Phase IIb trial in BPD (PORTICO, final results presented at ECNP-2024). Phase III in agitation/aggression in borderline personality disorder (BPD) in preparation. Vafidemstat is also being investigated for treating negative symptoms of schizophrenia in a randomized, double-blind Phase IIb trial (ongoing trial expansion to additional EU countries). Preparing a new Phase II trial in aggression in patients with ASD, including genetically-defined ASD subpopulations such as Phelan McDermid Syndrome. Iadademstat, a best-in-class LSD1 inhibitor, is in clinical development for AML, solid tumors and hematological disorders. PoC with strong clinical activity in combo with azacitidine in a Phase II in unfit AML patients, and encouraging signals in 2L-ED-SCLC. Highly encouraging data presented at ASH-2025 from ongoing trials in 1L AML (in combo with venetoclax/azacitidine, 100% ORR, 90% CR) and in R/RFlt3mut+ AML (in combo with gilteritinib, 67% CCR at the dose under expansion). Additional trials ongoing in MDS (in combo with azacitidine),1L SCLC (in combo with ICI), and in MPN (in combo with ASTX727). Expanding into hematological indications: sickle cell disease (PhIb trial approved by EMA, recruiting), essential thrombocythemia (PhII in prep).

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn and X.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi nec ex luctus, euismod ante vitae, dapibus massa. Fusce consequat maximus dui. Vivamus ipsum erat, pretium in gravida ac, lacinia a eros. Aenean rutrum dignissim egestas. Donec est ligula, egestas non finibus et, rutrum vitae urna. Ut semper, quam nec consectetur rutrum, purus arcu lacinia arcu, vitae vestibulum magna felis ac mauris. Aliquam lacinia blandit felis. Suspendisse vehicula enim non porttitor lacinia. Ut molestie lorem eget dignissim ultrices. Proin quis dui lacus. Vestibulum et fermentum mi. Duis dapibus orci risus, sit amet egestas dolor pellentesque ac. In non arcu elementum, tincidunt massa a, convallis nisl. Etiam non dictum nunc, nec convallis ligula. Aenean sed tempor lectus, ut mattis lacus. Vestibulum ante orci, cursus sed orci at, faucibus cursus sem. Integer convallis, lorem id feugiat accumsan, risus mauris sollicitudin magna, at rhoncus mauris nunc a tortor. Aliquam id vehicula magna. Quisque ut dolor justo. Duis mollis aliquam sem, sed egestas augue vehicula at.

STALICLA SA is a Swiss clinical-stage biopharmaceutical company, revolutionizing the treatment of neurodevelopmental (NDD) and wider neuropsychiatric disorders. The company has developed a clinically validated neuro precision development platform, successfully delivering stratified patient subgroups and advancing tailored treatment options. Its lead NDD asset, STP1, and a second NDD asset are set to enter Phase 2 trials with expected readouts within 30 months. STP7 (Mavoglurant), is also being advanced for Phase 3 trials, fully funded by the US government with discussions underway for out-licensing. We are currently raising a series C of $60m to recite the Phase 2 precision autism program development.

Synendos is a clinical stage neuroscience company pioneering new treatments for neuropsychiatric and neurological disorders, including anxiety and PTSD. By restoring the brain's natural balance through targeted modulation of the endocannabinoid system (ECS), Synendos aims to unlock a new generation of therapies that address the underlying causes of these conditions. Our lead candidate, SYT-510, is the first in a new class of ECS modulators known as Selective Endocannabinoid Reuptake Inhibitors (SERIs). This innovative approach is designed to provide sustained therapeutic benefits and improved tolerability, thereby helping more patients maintain treatment and achieve better quality of life.

Theranexus is an innovative biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company has a unique platform for the identification and characterization of advanced therapy drug candidates targeting rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Tonix is a fully integrated, commercial biopharmaceutical company focused on CNS and immunology.

Acasti is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Acasti's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Acasti's lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Acasti's lead clinical asset, GTX-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.

Acelot develops small molecules for challenging targets in diseases with high unmet need by harnessing cutting-edge computational tools to drug targets that lack complete structural information. Acelot’s first-in-class development candidate, ACE-2223, targets misfolded TDP-43 for the treatment of sporadic ALS. ACE-2223 disrupts misfolded TDP-43 and restores nuclear TDP-43 function and downstream protein splicing. ACE-2223 is well characterized in vitro and is the first orally bioavailable small molecule to show target engagement against misfolded TDP-43 and significant extension of survival in aggressive ALS animal models. ACE-2223 will begin first in human studies in spring 2026.

AgenT is a French life sciences company on a mission to defeat Alzheimer’s by targeting the silent phase. By combining multi-omics assays with advanced machine learning techniques, we found new blood biomarkers (not abeta or tau) deregulated from the earliest stages of the disease. Using this proprietary database, we are developing an accurate blood diagnosis and the next generation of precision therapies to treat Alzheimer’s. Our two blood tests, B-HEALED™ and B-AHEAD™, have been validated in a clinical validation involving 632 participants sampled up to 18 years prior to the dementia onset and coming from the US, Europe and Australia. We are pioneering a new method for detecting and treating Alzheimer's disease in its silent stage to prevent the onset of irreversible symptoms.

Bloom Science is redefining medicine by creating innovative therapies that harness the body’s natural metabolic and neurological pathways. Inspired by the therapeutic benefits of the ketogenic diet, Bloom’s approach targets multiple mechanisms simultaneously to provide safer, more effective solutions for obesity, Dravet syndrome, ALS, and other complex conditions. Our lead program, BL-001, is a live biotherapeutic product reverse engineered to replicate the ketogenic diet’s clinical efficacy. BL-001 has demonstrated proof of mechanism and has been observed to be safe and tolerable, with Bloom planning Phase 2 clinical trials in both obesity and Dravet syndrome. The IrisRx™ discovery platform powers Bloom’s pipeline by integrating cutting-edge science and a proprietary knowledgebase. This platform enables the development of novel, multi-pathway therapeutics through gut commensal microbes and synthetic biology, delivering innovative treatments with broad therapeutic potential. Backed by top-tier investors and a team of industry veterans, Bloom Science is advancing a deep pipeline to transform patient care and create lasting clinical impact.

GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of neurodegenerative diseases, such as Multiple Sclerosis (MS), Post-COVID (PASC) and Amyotrophic Lateral Sclerosis (ALS).

GliaPharm's pioneering approach is to stimulate energy utilization in the brain by targeting a type of glial cells called astrocytes, representing an innovative approach for the treatment of neurological and psychiatric disorders.

Kynexis is a new biotech company, backed by Forbion and Ysios. It is taking a novel approach to cognitive impairment associated with schizophrenia (CIAS) Cognitive impairment is a major cause of disability in a large majority of people with schizophrenia, and currently there are no approved drugs for CIAS. Dysregulation of the kynurenine pathway is hypothesized to cause schizophrenia, and we are taking a human biology-based, first-in-class approach to target CIAS with our lead molecule, KYN-5356. For decades, research on novel potential therapies for neuropsychiatric disorders relied primarily on animal models. At Kynexis, we use a human biology-based approach for our target rationale, a causal biomarker approach to assert our mechanism of action in clinical development, and a human genetics approach to identify responder sub-populations. We believe that this convergence of human data for rationale, biomarkers and genetics uniquely positions this program for success in CIAS and possibly additional indications as well.

First-in-class biotherapies against neurological diseases. Lys Therapeutics is a biotechnology company pioneering a revolutionary approach to treat unmet medical needs in patients suffering from neurovascular or neurodegenerative disorders by targeting blood-brain barrier (BBB) dysfunction. Targeting neuroinflammation to tackle neurodegeneration.

Neuro-Innovators, LLC (NIV) is a clinical stage drug company engaged in the commercialization of compound drugs that increase neuroplasticity, the brain’s capacity to remodel, rewire, recover. From its proprietary list of drugs with published neuroplastic properties NIV is designing combinations based on observed mechanisms of neuroplasticity and how each effects a specific condition. Candidate conditions range from: brain injuries, to chronic brain trauma, to neurodegenerative diseases. Since NIV is using only FDA approved drugs, NIV is able to follow the FDA’s 505(b)(2) and Fast Track processes, resulting in shorter time (3-5 vs. 10+ yrs) and lower cost (~$33M vs. $1+B for New Chemical Entity) to market. NIV’s first drug, NIV-001, targets patients with chronic motor deficits due to a stroke. This one market segment represents a substantial $20+ billion market. The 7M surviving US stroke patients cost society ~$50B annually, and create significant family, and community burdens. Importantly, this indication is associated with objective, measurable outcome metrics (motor deficits changes). Such clear statistical measures lowers FDA approval risks and clinical trial costs and shortens time to market. NIV has a letter of intent with a top tier Boston hospital to run its first human clinical study and is driving to close its seed funding of $2.6 M to start the study in Q1 2024. NIV’s Series A & B rounds will total $30M to execute both Phase 2(b) and Phase 3 studies. NIV expects to be an acquisition target in 3 yrs, and commercialize NIV-001 in 5-6 yrs.

Founded in 2010, Neuromod Devices Ltd. is a medical technology company headquartered in Dublin, Ireland. The company specializes in the design and development of bimodal neuromodulation technologies. Neuromod’s Lenire® device was granted FDA de Novo in March 2023 and has been subsequently rolled-out successfully in the US. Real world evidence data from Lenire providers confirm large clinical trial data on the efficacy of Lenire.

Newronika S.p.A. is a cutting-edge medical device company at the forefront of developing the world's most advanced Deep Brain Stimulation (DBS) system primarily designed for treating Parkinson's disease, tapping into a significant market valued at over $3 billion. The company has successfully pioneered the AlphaDBS system, a closed-loop DBS innovation distinguished by its proprietary control algorithm. This algorithm continually monitors brain signals, dynamically adjusting stimulation parameters to precisely align with each patient's therapeutic requirements. Beyond Parkinson's disease, Newronika's adaptive DBS system is a versatile platform technology, positioning the company to pursue approvals in diverse indications such as epilepsy, pain, and incontinence. This expansion broadens the total addressable market to well beyond $10 billion. Newronika has successfully secured funding through a Seed and Series-A round, along with prestigious grants, including a notable €2.5 million EIC grant. Currently, the company is actively raising a Series B round, targeting a substantial $30+ million. With over $10 million already committed to this fundraising effort, the proceeds will be allocated towards supporting the pivotal trial and implementing incremental product improvements, further solidifying Newronika's position as a leader in innovative medical solutions.

Parow Entheobiosciences (ParowBio) aims to develop proprietary, effective and accessible treatments for psychiatric conditions based on entheogenic (traditional psychedelics) molecules through a rigorous, science-based approach from discovery to clinical trials and manufacturing. ParowBio is an opportunity to obtain high potential, low-risk investment exposure to psychedelics biotechnology - offering innovative and effective therapeutics for mental disorders including depression, addiction, PTSD and obsessive-compulsive disorder (OCD). More than 10% of the US population suffers from these conditions and mental illness is among the leading contributors to the global burden of disease.

PATH BIOTECH LLC is a seed-stageAI-driven precision medicine company in the USA developing novel targets and therapeutics to treat neurological disorders and cancer. PATH BIOTECH developed a proprietary Precision Medicine Artificial Intelligence Therapeutics (PATH) platform to multi-omics big data from patients for cures of Alzheimer’s, cancer, and aging. We are currently funded by phase-1 NIH STTR grant to fast forward our IP-protected pharmaceutical products towards clinical study in Alzheimer's disease and dementia.Our founders composed a highly inter-disciplinary team, and our expertise range from AI/Machine Learning, biology, pharmacology, to biomedicine chemistry. All founders are tenured faculty at the University of Arizona, USA with decades of research experiences and well-funded federal research grants.

ProNeurogen is a clinical-stage biotech company developing novel peptide-based therapeutics to treat vascular dementia/mixed dementia and chronic pain. ProNeurogen therapeutics are also being developed for the treatment of ARIA in AD patients undergoing anti-amyloid antibody therapy. There are currently no FDA treatments for vascular dementia positioning ProNeurogen to be first-to-market for vascular dementia and mixed dementia. ProNeurogen’ s lead product, PNA5, will have its FDA IND in Q42023 and is expected to be begin human clinical testing in Q32024. ProNeurogen has developed a platform of glycosylated-Ang-(1-7) peptides for treatment of memory loss due to chronic inflammation as well as chronic pain. We have advanced and completed pre-clinical testing of our 2 lead compounds, PNA1 and PNA5 to treat dementia. PNA1 human studies have been used to de-risk the development of our lead candidates and is currently in Phase 2a trials for both vascular cognitive impairment and TBI. PNA5 has completed IND enabling studies and will begin human clinical trials in Q32024. Following completion of Phase II studies with PNA5 we will identify a large-pharma partner to complete Phase III trials and take product to market.

Psilera is a biopharmaceutical company developing groundbreaking therapeutics for hard-to-treat neurological conditions. Psilera’s diverse pipeline includes two partnered late stage programs with AtaiBeckley (BPL-003, 5-MeO-DMT phase III ready and VLS-01, DMT phase IIb) for treatment-resistant depression through an IP licensing transaction executed in early 2025. Furthermore, by utilizing their proprietary neuroplastogen drug design platform, Psilera has amassed a leading pipeline of next-generation neuroplastogens including PSIL-006, a first-in-class therapeutic for the treatment of frontotemporal dementia (FTD). With a deep commitment to scientific excellence and patient centricity, Psilera quests to provide treatment options to underserved patient populations throughout the globe. Welcome to the new era of mindful medicine.

Reunion Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions.

Sinaptica has developed a new form of personalized weekly brain stimulation for Alzheimer’s Disease (AD) that has been granted FDA breakthrough status based on unprecedented published sham-controlled Phase 2 data-- significantly slowing mild-to-moderate (M/M) AD on all functional and cognitive endpoints at 6 months, and on the primary and all key secondaries at 12 months in all three domains: cognition, function, and behavior, with virtually no side-effects. Sinaptica’s technology is a new powerful form of rTMS with personalization (via concurrent pairing with EEG), precision (via Neuronavigation) and a proprietary ML algorithm and treats AD by enhancing neuroplasticity via neuromodulation of the Default mode network (DMN), a novel brain network responsible for episodic memory and strongly implicated in AD. Sinaptica is emerging as a leader in personalized precision brain stimulation with a connectomics-based platform that can address multiple brain disease states, starting with Alzheimer's and MCI.

We bridge the gap between preclinical and clinical neuroscience by evaluating the performance of neurology therapeutic assets on the most clinically relevant in vitro platform available. Tessara leads the world with our RealBrain drug screening platform, combining reproducibility and scalability with human physiological relevance in 3D in vitro models. RealBrain models feature functional neural networks and closely mimic human neurophysiology. The RealBrain microtissues are cultured from neural precursor cells mixed with biomaterials in a one-step casting process that mitigates the typical limitations of in vitro technologies. Automation, developed through partnerships with robotics leaders, enables consistent, rapid production of microtissues with minimal variation. Furthermore, AI algorithms transform the neural architecture into digital 3D maps for automatic detection and quantification of neural network architecture. This allows precise assessment of drug effects on various cell populations and neural connectivity. Unique in its capability for high-throughput, high-content analysis, the RealBrain platform combines sophisticated biology with user-friendly handling, to accelerate drug discovery and predict which drug candidates are more likely to be efficacious in human clinical trials.

TIKOMED is a privately held company focused on development of ILB, a small molecule for neurological conditions, documented to phase 2 in ALS and with a MoA supporting several additional indication. TIKOMED is planning for IND and a Phase 2b study in ALS.

Zeto has made it possible for any health care facility to offer an easy, turnkey EEG solution to their patients. We provide a unique, wireless, FDA cleared, dry EEG headset that can be put on by any medical staff within 5 minutes. Live video and data can be interpreted seamlessly via the cloud, further enabled by AI based seizure detection, live EEG monitoring and interpretation services by board certified neurologists. Most importantly, EEG is a well reimbursed procedure with several well accepted CPT and DRG codes for billing, significantly enabling our adoption in the market.